Given our study analyzed EGFR amplification among 277 confirmed IDH-wildtype GBM patients with known MGMT status treated in the modern era, the negative finding suggests that EGFR amplification is likely not a meaningful prognostic biomarker for IDH-wildtype GBM. This evidence concerns the gene IDH2 and glioblastoma.